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improves survival of HIV-infected hemodialysis patients. Am J Kid-ease (ESRD), the lesser of the two evils may be to opt
ney Dis 36:574–580, 2000
for dialysis rather than a possible life-threatening oppor- 3. Ahuja TS, Borucki M, Funtanilla M, et al: Is the prevalence of
HIV-associated nephropathy decreasing? Am J Nephrol 19:655–659,tunistic infection in an attempt to preserve renal function
1999by the use of corticosteroids.
We completely agree with the authors that HAART
Reply from the authorsand angiotensin-converting enzyme (ACE) inhibitors
We thank Drs. Ahuja and Weiss for their comments.should be the first-line therapy for patients with HIVAN.
In our study, given the unequal follow-up period inOne very important intervention in preserving the long-
the corticosteroid-treated and non-corticosteroid–treatedterm renal function of patients with HIVAN is an early
groups, it is misleading to simply compare the numberdiagnosis and treatment with HAART and ACE inhibi-
of observed events, such as hospitalizations. Instead, ittors. In a previous study we screened 557 asymptomatic
is essential to compare the observed event rates (numberHIV-infected patients for HIVAN. Of the 10 patients
of events per unit of time of follow-up). Thus, in ourwith HIVAN two were diagnosed at an early stage of
study the actual observed (not extrapolated) serious in-the disease and were treated with HAART and ACE
fection rate was similar, and not significantly different,inhibitors [3]. Two years after the initial diagnosis and
in both the corticosteroid-treated and the non-corticoste-treatment, both patients have stable renal function (ab-
roid–treated groups, at 1 per 2.6 patient-months of fol-stract; Memon A, J Am Soc Nephrol 11:A0491, 2000).
low-up and 1 per 2.3 patient-months of follow-up, respec-We agree with Eustase et al that corticosteroid therapy
tively. We suspect that with the concomitant use of highlyshould be limited strictly to those patients with HIVAN
active antiretroviral therapy (HAART) the incidence ofwho have rapidly deteriorating renal functions and high
infection may have been reduced in the corticosteroid-CD4 counts.
treated as well as in the non-corticosteroid–treated
group. In the absence of any data, however, this possibil-Tejinder S. Ahuja and Vasanta P. Weiss
Galveston, Texas, USA ity remains purely speculative. We agree with Ahuja and
Weiss that early detection and treatment are essential
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in the successful management of HIV-associated ne-Department of Medicine, 4.200 John Sealy Annex, 301 University Boule-
vard, Galveston, Texas 77555, USA. phropathy (HIVAN).
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